WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform ...
FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases “The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives ...
Revvity, Inc. (NYSE:RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, ...
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST ...
(RTTNews) - Revvity, Inc. (RVTY), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. tuberculosis (TB) test. "The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback